even
though
chemotherapi
radiotherapi
hematopoiet
stem
cell
transplant
hsct
use
treat
hematolog
malign
sever
still
consid
incur
har
host
immun
system
toward
target
cancer
cell
destruct
shown
effect
therapeut
vaccin
leukemiaassoci
antigen
laa
among
approach
trigger
tumorspecif
immun
respons
identif
laa
cytotox
lymphocyt
ctl
epitop
major
import
develop
tumor
antigenspecif
therapeut
prophylact
vaccin
number
tcell
epitop
laa
identifi
peptid
vaccin
target
laa
base
tcell
epitop
shown
effect
clinic
trial
epiderm
growth
factor
receptor
pathway
substrat
contain
amino
acid
locat
chromosom
human
gene
encod
express
protein
molecular
weight
kda
refer
two
isoform
signal
adapt
regul
actin
cytoskeleton
dynam
architectur
particip
transduct
signal
ra
rac
activ
racspecif
guanin
nucleotid
exchang
factor
activ
form
trimer
complex
togeth
involv
regul
process
includ
dendrit
cell
migrat
well
cancer
cell
migrat
invas
strong
evid
demonstr
oncogen
potenti
overexpress
report
rang
human
malign
includ
breast
cancer
pituitari
tumor
pancreat
cancer
cervic
cancer
colon
cancer
head
neck
squamou
cell
carcinoma
esophag
cancer
human
glioma
amplif
often
associ
tumor
progress
acquir
drug
resist
poor
prognosi
upregul
thu
expect
involv
human
carcinogenesi
impli
gene
may
use
target
tumor
immunotherapi
previou
studi
group
demonstr
elev
express
patient
acut
myeloid
leukemia
aml
overexpress
invers
correl
overal
surviv
patient
protein
vaccin
reagent
induc
ctl
respons
murin
breast
carcinoma
model
aforement
fact
specul
gene
may
prognost
marker
could
target
immunotherapi
hematolog
malign
best
knowledg
tcell
epitop
report
date
aim
present
studi
identifi
human
leukemia
antigen
hla
epitop
achiev
aim
express
rang
tumor
cell
line
detect
use
western
blot
analysi
revers
transcript
quantit
polymeras
chain
reaction
rtqpcr
phenotyp
detect
use
direct
immunofluoresc
method
furthermor
screen
protein
sequenc
perform
use
variou
algorithm
predict
peptidebind
abil
hlaa
molecul
proteasom
cleavag
site
cterminu
identifi
tcell
epitop
find
valid
vitro
peptidebind
affin
assay
brefeldina
bfa
decay
assay
function
avid
candid
peptidespecif
ctl
evalu
use
enzymelink
immunosorb
spot
elispot
assay
cytotox
assay
four
peptid
ctl
epitop
identifi
may
use
vaccin
design
tumor
immunotherapi
lymphoblast
cell
line
design
cem
purchas
american
type
cultur
collect
cat
manassa
va
usa
cell
line
transport
associ
antigen
process
tap
defici
express
absenc
exogen
antigen
peptid
load
major
histocompat
complex
mhc
class
express
level
surfac
low
due
poor
stabil
nonpeptideload
mhc
class
molecul
human
erythroleukemia
cell
line
cat
human
acut
monocyt
leukemia
cell
line
cat
tchu
colon
cancer
cell
line
cat
human
breast
tumor
cell
line
cat
tchu
purchas
type
cultur
collect
chines
academi
scienc
shanghai
china
human
acut
myelogen
leukemia
cell
line
provid
tianjin
institut
hematolog
tianjin
china
cultur
dulbecco
modifi
eagl
medium
dmem
invitrogen
life
technolog
grand
island
ny
usa
cultur
iscov
modlfi
dulbecco
medium
imdm
invitrogen
life
technolog
contain
fetal
bovin
serum
fb
ge
healthcar
life
scienc
logan
ut
usa
cell
line
cultur
medium
invitrogen
life
technolog
supplement
fb
moll
lglutamin
iuml
penicillin
streptomycin
biolog
industri
israel
beit
haemek
ltd
beit
haemek
israel
cell
maintain
humidifi
incub
mous
antihuman
monoclon
antibodi
clone
number
conjug
fluorescein
isothiocyan
fitc
purchas
biolegend
san
diego
ca
usa
cat
rabbit
monoclon
antibodi
clone
number
purchas
abcam
inc
cambridg
usa
cat
dilut
secondari
goat
antirabbit
immunoglobulin
ig
g
antibodi
purchas
southern
biotechnolog
associ
inc
birmingham
al
usa
cat
dilut
mous
antigapdh
monoclon
antibodi
conjug
horseradish
peroxidas
hrp
purchas
kangcheng
biotech
shanghai
china
cat
kc
dilut
immobilon
western
chemiluminesc
hrp
substrat
purchas
merck
millipor
billerica
usa
lymphocyt
separ
medium
purchas
tianjin
haoyang
biolog
manufactur
co
ltd
tianjin
china
recombin
human
interleukin
il
purchas
peprotech
rocki
hill
nj
usa
bfa
purchas
sigmaaldrich
st
loui
mo
usa
phytohaemagglutininm
pha
purchas
biolog
industri
israel
beit
haemek
ltd
kibbutz
beit
haemek
israel
cell
lysat
proteinas
inhibitor
phenylmethanesulfonylfluorid
pmsf
bicinchonin
acid
bca
protein
assay
reagent
purchas
beyotim
institut
biotechnolog
nanj
china
cytotox
nonradioact
cytotox
assay
kit
purchas
promega
corp
madison
wi
usa
elispot
kit
purchas
ucytech
bioscienc
de
uithof
utrecht
netherland
trizol
reagent
sybr
green
qpcr
super
mix
purchas
thermo
fisher
scientif
inc
waltham
usa
primer
specif
human
gapdh
synthes
sangon
biotech
co
ltd
shanghai
china
identifi
potenti
tcell
epitop
hlaa
allel
screen
cover
wide
rang
popul
first
protein
sequenc
screen
best
bind
epitop
use
algorithm
syfpeithi
http
wwwsyfpeithid
bioinformat
molecular
analysi
section
bima
http
wwwbimascitnihgov
cutoff
score
adjust
syfpeithi
bima
peptid
match
two
criteria
share
two
algorithm
select
second
netchop
algorithm
http
wwwcbsdtudkservicesnetchop
use
predict
whether
select
peptid
first
step
would
cleav
cterminu
third
protein
sequenc
analyz
five
differ
algorithm
hlaa
includ
immun
epitop
databas
iedb
http
wwwiedborg
netmhc
http
wwwcbsdtudkservicesnetmhc
svmhc
http
wwwsbcsusepierresvmhc
epijen
http
wwwddgpharmfacnetepijenepijenepijenhtm
rankpep
http
imedmeducmestoolsrankpephtml
peptid
predict
least
four
algorithm
select
known
hlaa
carcinoembryon
antigen
ylsganlnl
use
posit
control
peptid
hbcagderiv
hlaa
peptid
eylvsfgvw
use
neg
control
peptid
peptid
synthes
use
standard
chemistri
chines
peptid
compani
hangzhou
china
puriti
determin
reversephas
chromatographi
ident
confirm
mass
spectrometri
lyophil
peptid
powder
dissolv
accord
manufactur
instruct
ultrapur
water
dimethylsulfoxid
biolegend
dilut
phosphatebuff
salin
pb
invitrogen
life
technolog
final
concentr
mgml
store
aliquot
use
evalu
bind
affin
candid
peptid
hlaa
molecul
classic
peptidebind
assay
perform
describ
dervillez
et
al
certain
modif
cell
tapdefici
hlaa
due
poor
stabil
nonpeptideload
hlaa
molecul
hlaa
express
level
surfac
low
exogen
peptid
abl
induc
accumul
hlaa
molecul
thu
upregul
hlaa
molecul
cell
may
detect
floresc
intens
exchang
reflect
peptid
bind
abil
hlaa
molecul
briefli
cell
incub
overnight
peptid
final
concentr
imdm
serumfre
medium
contain
human
final
concentr
humidifi
incub
follow
h
temperatur
rais
h
cell
harvest
gentli
transfer
steril
centrifug
tube
centrifug
g
min
subsequ
cell
wash
twice
firstli
serumfre
imdm
cell
stain
buffer
biolegend
cat
cell
stain
directli
antihlaa
monoclon
antibodi
conjug
fitc
min
analyz
use
elit
flow
cytomet
beckman
coulter
miami
fl
usa
three
duplic
well
set
group
experi
repeat
three
time
use
posit
control
use
neg
control
cell
without
ad
peptid
use
background
control
fluoresc
index
fi
calcul
use
follow
formula
fi
mean
fluoresc
intens
mfi
mfibackground
mfibackground
repres
valu
without
peptid
fi
indic
peptid
high
affin
hlaa
molecul
fi
indic
peptid
moder
affin
hlaa
molecul
fi
indic
peptid
low
affin
hlaa
molecul
bfa
decay
assay
perform
evalu
peptidehlaa
complex
stabil
describ
saini
et
al
certain
modif
briefli
cell
seed
per
well
plate
cultur
either
candid
peptid
control
peptid
final
concentr
overnight
serumfre
imdm
medium
contain
final
concentr
accumul
peptiderecept
class
molecul
cell
surfac
follow
h
incub
cell
wash
incub
bfa
dissolv
serumfre
imdm
h
cell
harvest
gentli
transfer
steril
centrifug
tube
centrifug
g
min
wash
resuspend
cell
stain
antihlaa
fluoresc
monoclon
antibodi
analyz
use
flow
cytometri
calcul
mfi
use
valu
timepoint
anoth
group
cell
treat
similarli
follow
wash
three
time
cell
resuspend
imdm
medium
presenc
bfa
incub
humidifi
incub
cell
harvest
gentli
transfer
steril
centrifug
tube
indic
time
point
centrifug
g
min
wash
stain
antihlaa
fluoresc
antibodi
stabil
peptid
bound
measur
defin
estim
time
requir
reduct
mfivalu
record
time
calcul
accord
formula
mfi
indic
time
point
mfi
time
three
duplic
well
set
group
experi
repeat
three
time
use
control
rtqpcr
perform
detect
rel
mrna
express
level
raji
cell
line
briefli
total
rna
extract
use
trizol
reagent
puriti
test
accord
ratio
optic
densiti
od
rna
integr
confirm
agaros
gel
electrophoresi
beyotim
institut
biotechnolog
rna
reversetranscrib
use
iscript
select
cdna
synthesi
kit
cat
biorad
laboratori
inc
hercul
ca
usa
random
nonom
primer
oligo
dt
primer
includ
synthes
cdna
purifi
total
rna
first
heat
denatur
min
reaction
system
establish
includ
rna
oligo
dt
random
primer
dntp
nm
rnase
inhibitor
buffer
mmlv
total
volum
reaction
condit
follow
min
min
min
quantif
pcr
product
accomplish
use
green
qpcr
supermixudg
cat
invitrogen
life
technolog
reaction
system
includ
cdna
sens
antisens
primer
gapdh
sybr
green
qpcr
super
mix
reaction
system
cdna
dilut
mix
sens
antisens
primer
gapdh
sybr
green
qpcr
super
mix
reaction
condit
follow
min
min
sec
sec
cycl
rel
quantit
express
sampl
evalu
detect
ct
valu
exchang
use
method
qualiti
cdna
confirm
pcr
analysi
gapdh
rtqpcr
use
abi
prism
sequenc
detect
system
appli
biosystem
foster
citi
ca
usa
perform
triplic
genespecif
pcr
primer
use
amplifi
gapdh
design
follow
sens
antisens
gapdh
sens
antisens
protein
express
level
cell
line
detect
use
western
blot
analysi
cell
maintain
indic
cultur
media
use
logarithm
growth
phase
cell
lyse
protein
extract
cell
lysat
use
ripa
lysi
buffer
presenc
proteinas
inhibitor
pmsf
protect
protein
degrad
pmsf
dissolv
isopropyl
alcohol
dilut
mmoll
protein
extract
procedur
pmsf
ad
ripa
lysi
buffer
volum
ratio
sampl
protein
concentr
determin
use
bca
protein
assay
accord
manufactur
instruct
prior
addit
sampl
load
buffer
beyotim
institut
biotechnolog
supernat
contain
protein
mix
protein
load
buffer
ratio
follow
boil
min
sampl
centrifug
store
use
total
sampl
electrophores
sdspolyacrylamid
gel
transfer
polyvinyliden
difluorid
pvdf
membran
merck
millipor
follow
block
skim
milk
beyotim
institut
biotechnolog
h
room
temperatur
membran
incub
h
skim
milk
ad
primari
antibodi
human
dilut
rate
membran
wash
three
time
trisbuff
salinetween
beyotim
institut
biotechnolog
incub
skim
milk
ad
hrpconjug
secondari
antibodi
dilut
rate
follow
addit
wash
membran
incub
immobilon
western
chemiluminesc
hrp
substrat
consist
luminol
reagent
peroxid
solut
captur
chemiluminescencesensit
film
sampl
gapdh
use
load
control
dilut
rate
briefli
cell
incub
recommend
medium
contain
fb
antibiot
describ
logarithm
growth
phase
cell
harvest
centrifug
g
min
resuspend
cell
stain
buffer
follow
centrifug
g
min
supernat
discard
cell
incub
human
trustain
cat
biolegend
per
cell
suspens
min
room
temperatur
fc
receptor
block
subsequ
cell
stain
directli
antibodi
conjug
fitc
incub
ice
min
dark
follow
wash
twice
cell
stain
buffer
centrifug
g
min
cell
resuspend
ml
cell
stain
buffer
cell
viabil
stain
solut
cat
biolegend
ad
exclud
dead
cell
cell
incub
ice
min
dark
analyz
flow
cytomet
hlaa
phenotyp
target
cell
detect
describ
imai
et
al
peptid
use
immun
peripher
blood
mononuclear
cell
pbmc
induc
peptidespecif
ctl
previous
describ
experi
approv
institut
ethic
committe
southern
medic
univers
guangzhou
china
inform
consent
obtain
donor
hlaa
phenotyp
analysi
donor
complet
use
pcrsequencebas
type
bgi
tech
shenzhen
china
pbmc
purifi
use
lymphocyt
separ
medium
pbmc
obtain
two
healthi
donor
incub
predict
peptid
final
concentr
medium
day
three
uml
ngml
ad
half
volum
medium
replac
fresh
medium
contain
final
concentr
uml
final
concentr
ngml
everi
day
day
seven
cell
harvest
gentli
pipet
transfer
steril
centrifug
tube
centrifug
g
min
follow
centrifug
cell
wash
resuspend
fresh
medium
contain
pbmc
repeatedli
stimul
peptid
everi
day
stimul
frequenc
least
three
order
harvest
suffici
number
ctl
time
antigen
signal
could
fulli
present
tcell
pbmc
week
stimul
cell
use
cytotox
assay
main
cell
total
pbmc
tcell
follow
three
time
peptid
stimul
ctl
harvest
use
function
analysi
whenev
necessari
cell
divid
evalu
peptid
immunogen
elispot
assay
perform
accord
manufactur
instruct
brief
pbmc
stimul
peptid
final
concentr
day
three
final
concentr
uml
ad
well
day
five
half
volum
medium
replac
fresh
medium
contain
final
concentr
uml
day
seven
pbmc
stimul
peptid
day
nine
microlit
plate
coat
overnight
monoclon
antibodi
day
cell
harvest
experi
peptid
final
concentr
ad
pbmc
per
well
xvivo
medium
lonza
group
ltd
auckland
new
zealand
cultur
humidifi
incub
follow
h
incub
content
well
discard
follow
wash
streptavidinhrp
solut
ad
well
plate
incub
hour
pvdf
membran
wash
thoroughli
ethylcarbazol
substrat
solut
ad
well
plate
incub
min
room
temperatur
dark
plate
wash
deminer
water
airdri
room
temperatur
follow
complet
experi
spotform
cell
sfc
count
dakota
biotechnolog
compani
shenzhen
china
experi
pha
stimul
use
posit
control
pbmc
without
ad
peptid
use
neg
control
serumfre
xvivo
medium
hebei
lonzer
chemic
co
ltd
handan
china
use
background
control
experi
group
perform
triplic
function
avid
peptidespecif
ctl
evalu
use
lactat
dehydrogenas
ldh
releas
assay
nonradioact
cytotox
assay
kit
use
detect
lysi
effect
ctl
target
cell
briefli
induc
ctl
use
effect
cell
cell
hlaa
cell
puls
correspond
peptid
cell
puls
irrelev
peptid
cell
cell
hlaa
cell
hlaa
use
target
cell
ratio
effect
cell
target
cell
set
constant
number
target
cell
cellswel
ad
effector
time
control
set
accord
manufactur
instruct
follow
centrifug
g
min
cell
incub
humidifi
incub
phenol
redfre
cultur
medium
contain
fb
h
fourtyf
minut
prior
supernat
harvest
lysi
solut
ad
target
cell
maximum
ldh
releas
control
cell
cultiv
continu
condit
subsequ
cell
centrifug
g
min
supernat
transfer
correspond
well
flatbottom
enzymat
assay
plate
ldh
measur
experi
perform
three
duplic
well
repeat
three
time
percent
cytotox
determin
use
follow
formula
cytotox
spontan
target
spontan
spss
softwar
spss
inc
chicago
il
usa
use
statist
analysi
oneway
analysi
varianc
use
compar
differ
group
p
consid
indic
statist
signific
differ
identifi
potenti
ctl
epitop
two
algorithm
syfpeithi
bima
use
predict
potenti
peptid
high
bind
abil
hlaa
molecul
limit
step
result
small
number
peptid
four
peptid
share
two
algorithm
select
algorithm
netchop
use
predict
whether
peptid
would
cleav
cterminu
peptid
cleavag
site
cterminu
select
final
five
differ
algorithm
use
confirm
select
peptid
four
peptid
start
posit
protein
sequenc
final
select
tabl
posit
neg
control
peptid
also
list
tabl
evid
suggest
peptid
affin
mhc
molecul
often
correl
immunogen
therefor
tapdefici
hlaa
cell
line
use
detect
peptid
affin
hlaa
molecul
exogen
peptid
ad
mfi
cell
increas
significantli
fig
four
candid
peptid
peptid
highest
affin
hlaa
mfi
fi
respect
fi
valu
two
peptid
almost
high
posit
control
peptid
mfi
fi
respect
indic
moder
affin
hlaa
molecul
p
fi
neg
control
tabl
weakaffin
peptid
found
four
candid
peptid
accord
definit
peptid
affin
hlaa
molecul
bfa
decay
assay
increas
time
mfi
cell
group
decreas
fig
calcul
reflect
peptidemhc
complex
stabil
longer
time
stabl
complex
complex
stabil
peptid
peptid
highest
h
follow
peptid
h
stabil
peptid
complex
lowest
h
tabl
identifi
candid
target
cell
rtqpcr
use
detect
mrna
express
furthermor
protein
express
detect
western
blot
analysi
among
eight
cell
line
mrna
express
level
fig
protein
express
level
fig
hlaa
phenotyp
target
cell
detect
direct
immunofluoresc
antibodi
stain
flow
cytometr
analysi
eight
cell
line
hlaa
fig
b
determin
immunogen
peptid
pbmc
stimul
procedur
describ
materi
method
section
follow
elispot
analysi
pbmc
separ
two
hlaa
healthi
volunt
repeatedli
stimul
peptid
secret
stimul
pbmc
respons
peptid
assess
two
donor
fig
pbmc
two
donor
respond
posit
stimul
four
predict
peptid
indic
increas
number
sfc
follow
stimul
note
pbmc
respond
strongli
stimul
rel
weak
binder
peptid
peptidespecif
cell
elicit
respons
lower
intens
strong
binder
peptid
cell
fig
p
character
function
avid
peptidespecif
ctl
ldh
releas
assay
perform
evalu
cytotox
effect
cell
puls
cognat
peptid
shown
fig
four
peptidespecif
ctl
effici
lyse
well
cell
puls
correspond
peptid
could
almost
lyse
cell
puls
irrelev
peptid
cell
effector
target
cell
ratio
p
peptid
ctl
highest
lysi
rate
cell
puls
correspond
peptid
averag
lysi
rate
cell
donor
fig
donor
fig
respect
lysi
rate
cell
load
correspond
peptid
donor
donor
respect
cytotox
effect
peptid
induc
ctl
target
cell
expressionspecif
restrict
hlaa
molecul
effector
target
hlaa
posit
cell
concept
treat
hematolog
malign
har
immun
system
establish
due
defect
current
treatment
method
hsct
potenti
method
cure
hematolog
malign
relaps
rate
remain
high
particularli
patient
transplant
relaps
second
subsequ
remiss
therefor
effort
requir
seek
novel
avenu
tumorspecif
synergi
current
treatment
method
viewpoint
therapeut
vaccin
laa
optim
choic
mount
evid
demonstr
exist
laa
laa
mute
immunogen
often
poor
howev
time
immun
evok
current
therapeut
vaccin
target
laa
far
optim
accordingli
isol
specif
compon
immunogen
induc
strong
immun
respons
ration
choic
vaccin
therefor
import
task
discoveri
cancer
vaccin
identifi
novel
taa
ctl
epitop
order
make
addit
therapeut
target
avail
close
associ
tumor
incid
progress
revers
immunolog
commonli
use
identifi
epitop
laa
present
studi
first
best
knowledg
report
potenti
taa
identifi
hlaa
epitop
report
express
elev
level
numer
human
malign
overexpress
report
suffici
transform
nontumorigen
human
cell
tumorigen
phenotyp
express
normal
tissu
type
rel
low
pivot
role
tumorigenesi
tumor
prolifer
invas
metastasi
furthermor
express
level
correl
diseas
sever
overal
surviv
patient
thu
taa
may
util
target
immunotherapi
cancer
well
hematolog
malign
present
studi
revers
immunolog
method
use
identifi
hlaa
epitop
predict
phase
appropri
select
tcell
epitop
contain
protein
focu
three
main
event
intracellular
gener
peptid
present
hla
class
molecul
hla
class
ligand
call
ctl
epitop
immunogen
first
event
enzymat
digest
protein
cytosol
peptidas
lead
releas
epitop
epitop
precursor
protein
second
import
event
requir
prevent
peptid
cytosol
degrad
via
tap
peptid
escap
cytosol
degrad
final
enter
endoplasm
reticulum
bind
hla
class
molecul
third
event
assembl
peptid
hla
class
heavi
light
chain
er
cell
surfac
present
peptid
process
present
three
step
highest
potenti
ctl
epitop
final
step
silico
analysi
five
differ
popular
algorithm
use
confirm
select
peptid
lead
final
select
four
peptid
worth
mention
aim
present
studi
identifi
domin
tcell
epitop
combin
predict
use
syfpeithi
bima
util
result
four
peptid
significantli
save
time
narrow
valid
scope
howev
indic
four
ctl
epitop
within
protein
sequenc
due
stringent
restrict
aris
select
criteria
sever
potenti
subdomin
epitop
may
ignor
bima
syfpeithi
base
principl
bind
motifsquantit
matric
spite
numer
novel
algorithm
emerg
remain
commonli
use
current
studi
main
reason
may
larg
dataset
compris
import
predict
datasetdriventh
bigger
dataset
accur
predict
one
weak
motif
quantit
matric
ignor
contribut
overal
peptid
structur
bind
overcom
limit
motifbas
predict
power
method
base
tool
includ
ann
pssm
smm
svmhc
use
report
sensit
specif
achiev
ann
togeth
proteasom
cleavag
tap
transloc
predict
specul
anchor
residu
select
peptid
could
chemic
complement
main
pocket
peptidebind
groov
hla
molecul
predict
peptid
alway
true
binder
sever
fals
posit
peptid
may
select
therefor
experi
requir
valid
immunogen
peptid
affin
hla
molecul
key
event
correl
hla
bind
immunogen
often
observ
erad
tumor
cell
tcell
requir
highaffin
target
peptidemhc
interact
lead
effici
crosspresent
antigen
bind
affin
hlaa
molecul
evalu
use
tapdefici
cell
line
exogen
peptid
ad
hlaa
molecul
surfac
accumul
result
chang
fluoresc
intens
chang
mfi
reflect
bind
affin
hlaa
molecul
four
peptid
peptid
highest
affin
hlaa
molecul
peptid
rel
low
bind
affin
hlaa
molecul
meant
peptid
like
ctl
epitop
howev
certain
peptid
high
bind
affin
hla
class
molecul
may
nonimmunogen
fail
form
stabl
complex
hla
class
molecul
although
peptid
immunogen
found
correl
significantli
high
affin
stabil
peptid
interact
mhci
correl
better
immunogen
affin
follow
identif
ctl
epitop
present
studi
assess
peptidemhc
complex
stabil
use
bfa
decay
assay
bfa
inhibit
protein
synthesi
cultur
cell
revers
inhibit
intracellular
transloc
protein
cell
surfac
secret
express
therefor
accumul
complex
remain
stabl
cell
peptidepuls
cell
continu
cultur
presenc
bfa
mfi
cell
decreas
peptidehlaa
molecul
complex
dissoci
natur
indic
molecul
complex
stabl
peptid
peptid
meant
peptid
may
immunogen
peptid
peptid
high
bind
affin
stabl
bind
peptid
mhc
vitro
necessarili
impli
peptid
natur
present
test
natur
present
candid
epitop
target
cell
first
screen
rtqpcr
western
blot
detect
express
hlaa
phenotyp
detect
direct
immun
fluoresc
antibodi
stain
flow
cytometr
analysi
three
tumor
cell
line
select
target
cell
epitop
identif
method
use
date
requir
induct
peptidespecif
ctl
follow
function
avid
evalu
pbmc
separ
healthi
donor
commonli
use
evalu
immunogen
peptid
two
hlaa
donor
identifi
among
healthi
volunt
use
extern
highresolut
method
peptidespecif
ctl
induc
immun
pbmc
two
healthi
hlaa
donor
least
two
round
weekli
stimul
peptid
presenc
number
peptidespecif
ctl
suffici
increas
follow
success
induct
specif
ctl
elispot
assay
use
quantifi
occurr
tlymphocyt
cell
secret
stimul
cognat
peptid
result
demonstr
four
peptidespecif
ctl
respond
correspond
peptid
secret
effect
sfc
met
criteria
posit
standard
number
sfc
peptid
specif
ctl
highest
result
two
donor
consist
meant
peptid
immunogen
three
peptid
final
recognit
effici
peptidespecif
ctl
target
cell
evalu
use
nonradioact
cytotox
assay
two
volunt
peptidespecif
ctl
could
lyse
hlaa
cell
puls
peptid
could
almost
lyse
either
hlaa
cell
effector
target
ratio
p
indic
cytotox
expressionspecif
hlaa
fashion
immunogen
peptid
strongest
togeth
elispot
result
demonstr
four
predict
epitop
natur
present
ctl
epitop
present
studi
observ
peptid
bind
affin
peptidehla
complex
stabil
correl
well
intens
immunogen
exampl
irrespect
low
affin
complex
stabil
hlaa
molecul
rel
weak
binder
peptid
stimul
pbmc
strongli
secret
highest
amount
strong
binder
peptid
stimul
least
amount
secret
pbmc
time
compar
mean
lysi
rate
ctl
induc
peptid
mean
lysi
rate
peptid
ctl
highest
puls
correspond
peptid
reason
may
base
interact
dynam
tcell
receptor
tcr
peptidemhc
complex
close
associ
tcell
activ
subsequ
differenti
fate
physiolog
affin
rang
optim
activ
tcell
plateau
tcell
function
activ
defin
affin
threshold
report
suggest
cluster
tcr
occupi
defin
threshold
increas
affin
contribut
tcell
function
therefor
defin
threshold
tcr
higher
avid
may
advantag
loweravid
tcr
exert
cytotox
function
furthermor
neg
feedback
mechan
includ
program
death
lymphocyt
activ
would
curtail
potenc
high
avid
tcr
discrep
observ
present
studi
may
ascrib
peptid
affin
highaffin
bind
peptid
defin
affin
threshold
anoth
reason
may
supraoptim
antigen
dose
evid
suggest
cultur
ctl
vitro
presenc
high
low
dose
antigen
lead
polar
low
highavid
respons
respect
regard
low
intermediateaffin
peptid
peptid
dose
use
ctl
induct
present
studi
may
supraoptim
highaffin
peptid
optim
tcr
stimul
peptid
dose
mainten
highavid
tcell
ex
vivo
ngml
result
retain
avid
prolifer
abil
kill
specif
target
contrast
supraoptim
tcr
stimul
peptid
dose
peptid
highavid
tcell
mainten
ex
vivo
result
reduc
avid
failur
kill
tumor
cell
present
studi
highlight
import
optim
stimul
induct
mainten
highavid
ctl
due
certain
limit
present
studi
explor
best
affin
hla
molecul
favor
peptidespecif
ctl
induct
mainten
furthermor
experi
present
studi
addit
drawback
first
due
limit
amount
blood
sampl
optim
cytokin
concentr
dose
interv
best
induct
mainten
peptidespecif
ctl
explor
second
background
signal
target
cell
lack
tumor
antigen
restrict
observ
impli
nonspecif
kill
effect
still
exist
reason
may
ascrib
use
bulk
ctl
instead
tcell
colon
effector
furthermor
cell
sort
pbmc
ctl
induct
begin
design
antigenpres
cell
dendrit
cell
dc
use
may
result
inadequ
antigen
process
present
despit
drawback
econom
practic
point
view
method
use
present
studi
econom
rapid
method
epitop
valid
furthermor
total
pbmc
includ
varieti
cell
type
includ
monocyt
dc
use
antigenpres
cell
apc
worth
mention
certain
ctl
epitop
identifi
vitro
may
less
immunogen
vivo
may
due
inadequ
antigen
process
present
apc
therefor
subsequ
studi
group
test
immunogen
epitop
vivo
use
transgen
mice
conclus
present
studi
identifi
four
hlaa
epitop
locat
start
posit
protein
sequenc
good
bind
affin
hlaa
molecul
peptidehlaa
complex
stabil
high
time
peptid
promot
lymphocyt
prolifer
specif
ctl
respond
correspond
peptid
secret
also
abl
recogn
lyse
target
tumor
cell
hlaa
manner
natur
process
present
tumor
cell
among
peptid
promis
antigen
epitop
target
tumor
cell
due
higher
immunogen
futur
studi
requir
investig
clinic
util
identifi
epitop
use
blood
sampl
patient
hematolog
malign
